Inhibition of PARP-1 in cancer has led to the marketing of four PARP-1 inhibitors for breast cancer and ovarian cancer, namely, Olaparib, Rucaparib, Niraparib, and Talazoparib. This evidence concerns the gene PARP1 and ovarian cancer.